Radiotherapy as salvage or consolidation therapy in advanced epithelial ovarian cancer
Survival results after treatment of advanced epithelial ovarian cancer are disappointing. While cisplatin alone or in combination produces response rates of approximately 60–80% in advanced disease, the initial optimism that overall cure rates in ovarian cancer would be substantially improved has not been fulfilled. The duration of relapse-free time has been increased over that achieved with single agent alkylating agents, but only 5–10% more patients are long term disease-free survivors . Overall cure rates in advanced disease remain about 20–30% [2–4]. One strategy that has been generally pursued in improving treatment outcomes in solid tumours has been to attempt to combine effective therapies sequentially or concurrently, particularly if their toxicities are non-overlapping.
KeywordsOvarian Cancer Ovarian Carcinoma Epithelial Ovarian Cancer Minimal Residual Disease Advanced Ovarian Cancer
Unable to display preview. Download preview PDF.
- 1.Neijt, J.P., ten Bokkel Huinink, W.W., van den Burg, M.E.L. et al (1991) Long term results of chemotherapy in advanced (FIGO Stages III or IV) ovarian cancer. Int. Gynecol Cancer Soc., (abstract), 36.Google Scholar
- 9.Mangioni, C., Epis, A., Vassena, L. et al (1987) Radiotherapy (RT) versus chemotherapy (CH) as second line treatment of minimal residual disease (MRD) in advanced epithelial ovarian cancer (EOC) Proceedings of the International Gynecological Cancer Society October, Amsterdam.Google Scholar
- 16.Piver, M.S., Barlow, J.J., Lee, P.T. and Vongtama, V. (1975) Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laparotomy and radiation therapy. Am. J. Obstet, Gynecol 122, 355–7.Google Scholar
- 36.Dembo, A.J., Bush, R.S. and Brown, T.C. (1982) Clinicopathological correlates in ovarian cancer. Bulletin du Cancer (Paris) 69292–8.Google Scholar